Longitudinal monitoring by next‐generation sequencing of plasma cell‐free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors

Abstract Background Patients with ALK‐rearranged non‐small cell lung cancer (ALK+ NSCLC) inevitably acquire resistance to ALK inhibitors. Longitudinal monitoring of cell‐free plasma DNA (cfDNA) next‐generation sequencing (NGS) could predict the response and resistance to tyrosine kinase inhibitor (T...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Minsuk Kwon, Bo mi Ku, Steve Olsen, Sehhoon Park, Martina Lefterova, Justin Odegaard, Hyun‐Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn
Format:	Article
Language:	English
Published:	Wiley 2022-08-01
Subjects:	anaplastic lymphoma kinase‐rearranged (ALK+) NSCLC cell‐free DNA liquid biopsy next‐generation sequencing
Online Access:	https://doi.org/10.1002/cam4.4663